41 results on '"Abuhadra, Nour"'
Search Results
2. ASO Visual Abstract: Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer
3. Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer
4. The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review
5. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy
6. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions
7. Impact of TP53 mutations in Triple Negative Breast Cancer
8. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
9. Online and Social Media Resources for Patients with MDS
10. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial
11. Supplementary Table from Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer
12. Supplementary Figure from Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer
13. Data from Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer
14. Abstract OT1-03-01: XMT-1660: A Phase 1b trial of a B7-H4 targeted Antibody Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers
15. TP012/#1420 XMT-1660: a phase 1B trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers
16. Beyond HER2: Targeting the ErbB receptor family in breast cancer
17. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer
18. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer
19. Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
20. Management and Outcome of Patients With Langerhans Cell Histiocytosis and Single-Bone CNS-Risk Lesions: A Multi-Institutional Retrospective Study
21. The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
22. XMT-1660: A Phase 1b trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers (1250)
23. Abstract PS8-04: Clinical and pathological characteristics and screening outcome for secondary cancers in breast cancer patients with li-fraumeni syndrome attending the MD anderson li-fraumeni education and early detection program clinic
24. Abstract PS4-05: Prospective evaluation of the gut microbiome and response to neoadjuvant therapy (NAT) in early-stage triple negative breast cancer (TNBC)
25. Abstract PS18-04: Prospective evaluation of patients with metaplastic (Mp) triple negative breast cancer (TNBC): Molecular characteristics and outcomes with neoadjuvant therapy (NAT)
26. Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC).
27. Abstract P1-10-20: Serial TILs: Evaluating the role of mid-treatment tumor infiltrating lymphocytes (TIL) in predicting pathologic complete response (pCR) in early-stage triple negative breast cancer (TNBC)
28. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy.
29. BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes
30. Impact of social media for the hematologist/oncologist
31. BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes
32. Epilepsy in Qatar: Causes, treatment, and outcome
33. XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.
34. Prospective evaluation of pathologic response with neoadjuvant chemo-immunotherapy in metaplastic breast cancer.
35. Impact of neoadjuvant chemo-immunotherapy on surgical outcomes and time to radiation in triple negative breast cancer.
36. Mutational Signatures Associated with Intensity and Duration of Smoking in Myelodysplastic Syndromes (MDS)
37. A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (MDS)
38. Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)
39. BCORMutations in Myelodysplastic Syndromes (MDS): Mutation Characteristics Impact Clinical Outcomes
40. Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS)
41. BCORand BCORL1mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.